In 1960, Dr Bayard Clarkson described a woman experiencing sporadic recurrent episodes of shock and anasarca. Plasma from an acute attack induced a shock-like syndrome when injected into rats. The enigmatic systemic capillary leak syndrome (SCLS) named for Dr Clarkson is characterized by transient and severe but reversible hemoconcentration and hypoalbuminemia caused by leakage of fluids and macromolecules into tissues. Although less than 500 cases of SCLS have been reported in the literature since 1960, the condition is probably underdiagnosed because of a lack of awareness and a high mortality without treatment. Allergists should be vigilant of this diagnosis because its presentation can resemble more common plasma leakage syndromes, including angioedema or systemic anaphylaxis. Although the precise molecular cause of SCLS remains unknown, substantial advances over the last 5 years have increased our understanding of SCLS pathogenesis. (J Allergy Clin Immunol 2017;140:663-70.)
Key words: Vascular leak, anaphylaxis, angioedema, intravenous immunoglobulin Dr Clarkson's index patient exemplifies systemic capillary leak syndrome (SCLS): an otherwise healthy 34-year-old woman with sudden-onset low-grade fevers; progressively decreasing blood pressure; rapid swelling of the face, arms, and legs; and increasing hematocrit levels despite intravenous fluid resuscitation. The unexplained shock and anasarca were followed several days later by a period of massive diuresis and diminution of peripheral edema. The patient eventually died of pulmonary edema and cardiac failure during the diuresis phase of an attack.
Dr Clarkson demonstrated that the albumin-binding dye T-1824 (Evans blue) was quickly cleared from the intravascular compartment in a patient experiencing acute attack, suggesting a primary role for vascular endothelial hyperpermeability (VEH). 1 Although studies of thyroid, gonadal, and adrenal steroid function and tests of immune and metabolic function available at the time were unremarkable, an anomalous gamma globulin (''paraprotein'') was identified in the serum of the index patient. We now know that this monoclonal gammopathy of unknown significance (MGUS) is present in 68% to 85% of patients with SCLS. 2 In this review we discuss the diagnosis of this rare and often fatal disease, clinical management of acute SCLS, prophylactic considerations, and new mechanistic concepts gleaned from recent studies. Increased recognition of SCLS and an improved understanding of pathophysiology are vital to improving outcomes.
INCIDENCE OF IDIOPATHIC SCLS
In our previous survey of the SCLS literature, we found 126 cases that were reported between 1960 and 2010. 3 Over the last 6 years, 134 new cases of SCLS have been identified, including a European registry of 28 cases 50 and our National Institutes of Health (NIH) cohort of 58 patients. 51 The demographics of these patients are described in Table I . SCLS occurs sporadically and has been described most commonly in middle-aged white adults (median age at diagnosis, 48 years; age range, newborn to 85 years). Because our cohort and the published literature now includes patients of Asian, African American, Hispanic, and Middle Eastern ancestry, the purported white predominance might simply reflect unawareness of this rare condition in some parts of the world. There is no sex predominance (52% were female). SCLS has also been reported in 14 children during the past 6 years. wheezing, or stridor, are not observed on presentation; and allergy therapies, including corticosteroids, epinephrine, or antihistamines, have proved largely ineffective in patients with SCLS. 53, 54 Nonetheless, inflammation is intimately linked to disease flares. In the European case registry approximately three fourths of subjects experienced a virus-like prodrome immediately before attacks. 50 In our review of individual cases published over the last 6 years, the NIH cohort, and the European registry, 44% had a readily identifiable trigger for flares, which included infections (typically upper respiratory), such as influenza, respiratory syncytial virus, and West Nile virus (39% [52/134] ). Other potential triggers included intense physical exertion, particularly when coupled with heat exposure, or extended travel, which occurred in 5% of the cases reported (7/134).
Patients with the classical acute form of SCLS rapidly experience shock and anasarca caused by plasma extravasation (up to 70% of total plasma volume). We have termed this the ''leak'' phase, which usually lasts for several days. Because there are no uniform criteria to fully define recovery from flares (eg, hemodynamic stabilization, resolution of edema, and normalization of renal function), it is difficult to assess episode duration precisely from case reports. However, based on our analysis of 30 of the cases published over the last 6 years in which such information was provided, the median duration of SCLS episodes is 3.8 days (range, 1-27 days). Visceral spaces, including the central nervous system or lungs, do not contain edema in patients with classical SCLS, although pleural and pericardial effusions, ascites, and even edema of the gastrointestinal tract wall have been detected during disease flares.
Severity and frequency of SCLS flares vary considerably across patients and can change over time. In the NIH cohort the frequency of attacks ranges from once every 10 years to once every 3 to 5 days. Similarly, in the European registry the median annual attack frequency was 1.23 (range, 0.13-21.18). 50 Gousseff et al 50 classified SCLS episodes as ''severe'' based on the presence of 1 or more of the following: (1) systolic blood pressure of less than 60 mm Hg; (2) mean blood pressure of less than 65 mm Hg; (3) loss of consciousness; and (4) admission to the intensive care unit. Some patients for whom we have cared have experienced milder events characterized by a smaller decrease in blood pressure; fatigue, weakness, and/or dizziness; increased thirst; decreased urinary output; and mild edema of the extremities that might only manifest as muscle tightness or discomfort. A third subset of patients can experience unexplained noncyclical peripheral edema but not acute hypotensive episodes, which we have designated ''chronic'' SCLS. The postleak phase usually begins 48 hours to 1 week after the onset of shock, in which fluids are mobilized from peripheral tissues into the intravascular space, followed by normalization of blood pressure and diuresis. Death from SCLS typically occurs during the postleak phase because of pulmonary edema arising from therapeutic intravenous fluid administration during the earlier leak phase.
Complications of acute SCLS crises relate to hypoperfusionrelated multiorgan dysfunction syndrome (MODS), hypercoagulability caused by hemoconcentration and increased serum viscosity, and anasarca. In our cohort these phenomena led to acute renal failure (14% of patients), thrombosis or pulmonary embolism (14%), and pericardial effusions/cardiac tamponade (9%). 55 Commonly, the massive peripheral edema associated with SCLS episodes results in compartment syndromes of the extremities, necessitating fasciotomies (50%) to treat rhabdomyolysis. Nearly one third of our patients have experienced permanent disability as a result of these muscle complications, including sensorimotor neuropathy, foot drop, and even limb amputations.
DIAGNOSTIC CONSIDERATIONS
The SCLS diagnostic triad is composed of the ''3 Hs'': (1) hypotension (typically systolic blood pressure <90 mm Hg); (2) hemoconcentration (hematocrit >49% to 50% in men and 43% to 45% in women), and hypoalbuminemia (<3.0 g/dL) in the absence of secondary causes for such abnormalities. Fluid resuscitation is typically followed by rapidly developing symmetric edema of the face, trunk, and extremities. As hemoconcentration worsens because of vascular leak, hemoglobin values continue to increase, often to greater than 20 g/dL, even after intravenous administration of saline. In several of our patients, this striking paradox has led to a mistaken diagnosis of polycythemia vera and unnecessary phlebotomy. Serum albumin and total protein levels can be within the normal range initially but decrease rapidly as protein extravasates. The initial evaluation includes measurement of routine blood and urine cultures to exclude sepsis and serum tryptase to rule out anaphylaxis and serum immunofixation electrophoresis to determine whether a paraprotein is present. In the 134 cases we identified over the last 6 years, 68% overall had MGUS, most commonly of the IgGk isotype. This was present exclusively in adults and not in any children with SCLS. Because there are no validated biomarkers and MGUS is not specific to this syndrome, SCLS remains a clinical diagnosis.
Additional tests can help evaluate other potential causes of hypotension, edema, or both. Urinalysis is necessary to exclude proteinuria as a primary cause of hypoalbuminemia and edema (eg, nephrotic syndrome), particularly in patients with chronic SCLS. Neuroendocrine tumors, such as carcinoid or pheochromocytoma, or inferior vena cava syndrome resulting from obstructing tumor or coagulopathy can be associated with acute hypotension, but they are not typically associated with high hemoglobin or low serum albumin levels. Complement studies, such as C3, C4, and CH50 measured during an acute SCLS event, might not be useful to exclude hereditary forms of angioedema. Serum levels can be low because of leakage of complement proteins rather than pathway activation. Nonetheless, we routinely assess C1 esterase inhibitor levels and function to exclude type I and II hereditary angioedema. Chest radiography, electrocardiography, pro-brain naturietic peptide measurement, and echocardiography help exclude primary congestive heart failure. Although overt heart failure is not a feature of SCLS, edema can occur in the heart muscle itself and contribute to contractile dysfunction. Myocardial edema without inflammatory infiltrates was seen in 3 of 4 biopsies reported in the literature, including a postmortem examination in a patient in the NIH cohort who died of acute SCLS. 13, 14, 33, 56 We have obtained evidence of myocardial edema in patients with active SCLS using cardiovascular magnetic resonance imaging. 56, 57 Dynamic measurement of extracellular volume (ECV) of heart tissue by using cardiovascular magnetic resonance imaging of gadolinium contrast agents is a novel means to detect active vascular leak in vivo. Calculation of the ECV is based on measurement of the longitudinal relaxation time constant (T1) of tissue before and after administration of a gadolinium-based contrast agent, which is exclusively present in the extracellular space. 58, 59 Myocardial ECV was significantly greater in patients with active symptoms of SCLS (Fig 1) , 56, 57 suggesting myocardial vascular leak. Finally, we have observed a transient decrease in left ventricular ejection fraction (to approximately 10% to 15%) during an episode in several young men without prior cardiac history. We speculate that this could result from Takotsubo syndrome or stress-induced cardiomyopathy, which might relate to the high doses of vasopressors needed in these patients. 60 
PATHOPHYSIOLOGY OF SCLS: THE ROLE OF VEH
A definitive mechanism for acute SCLS remains lacking; thus treatments have been developed by using trial and error. Although lymphatic abnormalities have not formally been excluded, albumin turnover studies suggest that vascular barrier dysfunction leading to VEH could account for the clinical phenotype.
1 Histopathology of the peripheral microvasculature from patients' biopsy specimens has not shown gross anomalies, evidence of disrupted angiogenesis, or the presence of inflammatory cells, complement, or immunoglobulin to suggest a vasculitis. 3, 26, 49 The absence of persistent structural abnormalities is consistent with a defective but reversible barrier dysfunction response of the blood vessels. Several results suggest the presence of humoral factors promoting VEH during disease flares: (1) transient spikes in monocyte/macrophage-associated inflammatory mediator levels during flares; (2) transient increase in circulating angiogenic protein levels during flares 51, 61 ; and (3) impairment of in vitro microvascular endothelial cell (EC) barrier function provoked by sera from patients with acute but not convalescent SCLS. 61, 62 Levels of the proinflammatory mediators CXCL10, CCL2, and IL-6 were increased in acute sera of 36 patients with SCLS compared with either convalescent sera or healthy control sera. Monocytes from patients with SCLS produced more CXCL10 than those from healthy control subjects. 51 Because none of these factors is specific to SCLS, these abnormalities might reflect a cytokine/chemokine upregulation induced by common infections that are suspected triggers for SCLS crises (eg, viral urinary tract infection). Levels of known angiogenic permeability factors, including vascular endothelial growth factor (VEGF) and angiopoietin 2 (Angpt-2), also appear to be transiently increased around disease flares. In the NIH study of 36 cases, VEGF and Angpt-2 levels were significantly increased in acute sera relative to those in convalescent sera. Serial measurements in several patients revealed that VEGF levels spiked at the very onset of symptoms and decreased rapidly, whereas Angpt-2 levels peaked later and decreased more slowly. 61 The ephemeral cyclical pattern of SCLS flares and the absence of chronic edema during remission periods suggests that endothelial barrier function returns to normal between crises.
Circulating factors induced during acute SCLS flares provoke EC barrier dysfunction through canonical mechanisms. For example, vascular endothelial (VE)-cadherin is an EC-specific adherens junction protein the homotypic interactions of which between adjacent cells are necessary for intact barriers. 63 Virtually all of the major signaling pathways that modulate barrier function ultimately reduce junctional localization of VEcadherin. Sera from patients with acute SCLS but not basal sera from patients with SCLS attenuated membrane VE-cadherin in microvascular EC monolayers and also induced actin stress fiber formation (Fig 2) . EC contraction and temporary attenuation of adherens junctions might permit leakage of solutes and proteins into the extravascular space during acute episodes.
Blockade of Angpt-2 with a neutralizing peptide attenuated acute SCLS sera-evoked EC barrier dysfunction in vitro, suggesting a pathogenic role for the Angpt-2 pathway. 61 Angpt-2 and Angpt-1 are ligands of the receptor Tie2 (Fig 3) . [64] [65] [66] Angpt-1 counteracts barrier dysfunction and VEH signaled by diverse mediators, spanning inflammatory molecules, bacterial products, and angiogenic factors. 67 Angpt-2 is considered a contextdependent antagonist of Tie2. Angpt-1 signals through Tie2 to stimulate NADPH oxidase and nearby Rac1. Active Rac1 promotes barrier defense by stabilizing VE-cadherin and inducing cell spreading. Active Rac1 is stabilized by IQGAP1, and it also signals through p190RhoGAP to inhibit RhoA, a related small-molecule GTPase that favors cell contraction, junction destabilization, and loss of barrier integrity. Hypomorphic genetic manipulations of p47phox, IQGAP1, or p190RhoGAP induce an EC phenotype similar to what we might predict in patients with SCLS: minimal basal abnormalities yet unusual susceptibility to otherwise ordinary inflammatory stressors. 64, 65, 68 To test the possible contribution of the Angpt-Tie2 pathway and/or other permeability inducers to SCLS, we have expanded blood-outgrowth endothelial cells (BOECs) from circulating precursors obtained by means of venipuncture. These cells possess structural and molecular characteristics of mature ECs. 69 Preliminary results suggest abnormal gene expression patterns in BOECs from patients with SCLS compared with those from healthy control subjects. 70 RNA sequencing of BOECs from patients with SCLS and those from healthy subjects highlighted several gene products, including Angpt-1 and its receptor, Tie2, and pathways that were markedly dysregulated in the BOECs from patients with SCLS. Among the most notably induced pathways were cellular movement, migration requiring loss of the stable intercellular contacts and cytoskeletal shape required for barrier defense, and the inflammatory response itself (Fig 4, see highlighted box) . The RNA sequencing results are consistent with our published observations that the physical mechanism of VEH in patients with SCLS is related to structural rearrangements between adjacent microvascular ECs, resulting in paracellular gaps. In the near future, ECs from patients with SCLS derived from induced pluripotent stem cells will also be tested for their responses to inflammatory mediators to determine whether the primary defect in SCLS lies in the endothelial compartment.
The role of specific gene defects in patients with SCLS, if any, is also unknown, such as whether the endothelium is genetically programmed for hyperresponsiveness to routine stimuli. There are no consistent familial aggregations in patients with SCLS. 3, 54 In one reported case of familial SCLS, the index case was correctly diagnosed, but the diagnosis of SCLS was not firmly established in the relatives. 71 The sporadic occurrence of SCLS and lack of pedigrees could be consistent with rare genetic events, such as compound heterozygosity (both alleles mutated and defective but at different locations) 72 or 2 or more rare hemizygous mutations in different genes, autosomal recessive inheritance with incomplete penetrance, or somatic mutations confined to 1 or more cell lineages. Such abnormalities might be difficult to detect with standard whole-exome sequencing.
To determine the contribution of genetic abnormalities to the SCLS phenotype, we performed a genome-wide association study of 12 patients and 18 control subjects (which included several asymptomatic relatives with no history of the disease). 73 From unbiased high-density mapping of single nucleotide polymorphisms, a small genetic interval, 3p25.3, was identified as the highest-ranking candidate susceptibility locus (P ; 10 26 ) with an odds ratio of approximately 41. Odds ratios (7 to 41) and P values (8 3 10 24 and 4 3 10 26 ) for the top SCLS-associated variants were outsized for such a small sample size. These results imply high penetrance for a rare disease allele that remains to be identified. The role of the paraprotein present in most sera of patients with SCLS, if any, is unknown. Although the monoclonal immunoglobulin could act as an autoantibody to promote VEH during acute episodes, limited prior studies have not identified a common target antigen or cell. In fact, treatment of healthy ECs with purified SCLS immunoglobulin in vitro did not induce cytotoxicity, activation, or morphologic abnormalities. 61, 74, 75 We speculate that if the paraprotein contributes to disease pathogenesis, a cofactor confined to disease flares might be required to unmask its activity because the immunoglobulin is also present during convalescent periods.
TREATMENT OF ACUTE SCLS
All treatment strategies are based on observational data rather than controlled trials because of disease infrequency. Patients presenting with hypotension and hemoconcentration consistent with acute SCLS should be treated in an intensive care setting with intravenous fluids sufficient to counteract intravascular volume depletion, maintain organ perfusion, and avoid severe metabolic acidosis (Fig 5) . It is unclear whether continuous crystalloid infusion is superior to boluses of saline or proteincontaining solutions, such as albumin, but theoretically, albumin might have a longer half-life in the bloodstream and promote intravascular volume expansion because of its reverse oncotic effects. The benefits of maintaining normotension and normal central venous pressure (4-8 mm Hg) might outweigh the risk of excessive fluids leading to compartment syndromes. Interestingly, a recent case report found increased levels of methemoglobin in a patient with SCLS during a severe episode, which is suggestive of increased nitric oxide production contributing to hypotension. 19 The authors reported that a single intravenous bolus of methylene blue, which neutralizes nitric oxide, sustainably Fig 3, B) or p47Phox (Fig 3, C) . Results are normalized to respective genetic controls to illuminate differences in responses to LPS. ****P < .0001, 2-way ANOVA. Adapted from Ghosh et al, 64 Mammoto et al, 65 and Ghosh et al.
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FIG 4. RNA sequencing of BOECs from patients with SCLS implicates persistent promigratory and proinflammatory responses. Ingenuity pathway analysis of RNA sequencing results from 6 BOECs from patients with SCLS versus 6 BOECs from control subjects organized by using the Benjamini-Hochberg (B-H)-corrected P value. Dash, P 5 .05. The highlighted box indicates categories with particular functional relevance to SCLS.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 3 reversed severe hypotension in their patient. Subsequently, we found that methylene blue administration had no pressor effect in a patient of ours (unpublished data). Metabolic abnormalities include lactic acidosis and increased creatinine phosphokinase and/or liver transaminase levels. Shortlived oliguria is common and does not necessarily require invasive renal replacement therapy in the absence of traditional indications. Deep venous thrombosis can occur because of severe hemoconcentration, increased serum viscosity, and stasis resulting from hypovolemia and compartment syndrome. Chronic anticoagulation should be considered in patients who experience thrombotic events during episodes. Monitoring of extremity compartment pressures by an orthopedic specialist is highly recommended to assess the need for fasciotomy and muscle debridement to prevent muscle and nerve necrosis. Studies suggest that the risk for such outcomes is higher when intracompartmental pressures are greater than 40 mm Hg. 76 During the postleak phase, aggressive diuresis is arguably the most important intervention to prevent flash pulmonary edema.
Both mild and severe acute SCLS episodes are self-limited by nature. Because vascular leak associated with SCLS nearly always remits spontaneously after several days, it is inherently difficult to assess the efficacy of acute interventions. We have found no conclusive evidence that anti-inflammatory agents, including corticosteroids, can abort or delay the progression of an acute SCLS attack. Similarly, although therapeutic targeting of factors linked to acute SCLS flares (eg, VEGF and TNF-a) have been used in isolated cases, 75, 77 compelling evidence for use of these strategies is lacking. However, a recent SCLS case report suggested the possibility of adrenal and thyroid deficiency arising from extravasational loss of hormones and their serum binding proteins, 15 providing a rationale for the use of stress-dose steroids (and perhaps even thyroid replacement) in the initial management of an episode. Theophylline has been reported to be effective in the treatment of acute SCLS. 77, 78 Based on published cases, our own experience, and its theoretical ability to counteract VEH (see below), we currently recommend administration of aminophylline intravenously for severe flares. Finally, Lambert et al 79 reported that administration of high-dose intravenous immunoglobulin (IVIG; 1-2 g/kg) rapidly corrected hypotension and promoted diuresis in 3 patients with acute flares. Although we have not observed comparable rapid effects of IVIG in 2 hospitalized patients (unpublished data), quantitative studies of in vivo vascular barrier function before and after such acute treatments might inform IVIG's application as a rescue therapy.
PROPHYLACTIC THERAPY AND PROGNOSIS
Although the utility of potential disease-modifying agents in patients with acute SCLS remains uncertain, it has become abundantly clear over the last several years that prophylactic therapy is highly beneficial. Gousseff et al 50 reported a 5-year mortality rate of 15% in those receiving maintenance therapies versus 80% in those who had not. A Mayo Clinic study of more than 25 patients with SCLS showed that terbutaline and theophylline administered orally significantly reduced the frequency and severity of SCLS episodes. 54, 80 The rationale for use of these drugs is their ability to increase intracellular cyclic AMP levels, which might counteract inflammatory signaling pathways that induce endothelial permeability. 81 Intracellular cyclic AMP is thought to exert its actions on EC barrier function through 2 principal effectors: protein kinase A and the guanine nucleotide exchange factor for Rap GTPases (Epac). Rho family GTPases, such as RhoA, promote myosin light chain kinase phosphorylation, which in turn induces actomyosin bundling and cell contraction, a principal mechanism of VEH. By increasing Rap and protein kinase A activity, cyclic AMP inhibits RhoA and attenuates cortical actin remodeling and destabilizing VE-cadherin junctional interactions to fortify the vascular barrier. 82 Although several of our patients have responded well to this regimen, our experience and a review of case reports published over the last 6 years suggest that nearly 84% of patients broke through this treatment with disease flares (Table I) . Although some of the episodes were associated with ''suboptimal'' serum theophylline levels (based on ranges that have been used for asthma), it should be noted that therapeutic ranges for SCLS have not been established. In addition, these drugs were poorly tolerated because of side effects, such as tremor, irritability, palpitations, and insomnia. 55 Based on its potential immunomodulatory and anticytokine properties, IVIG has been widely used for the treatment of autoimmune and MGUS-associated syndromes. 83, 84 The mechanism of action of IVIG in patients with SCLS is unknown, but we speculate that anti-idiotypic effects on the putative mAb or neutralization of proinflammatory cytokines by antibodies present in IVIG preparations are 2 possible mechanisms through which IVIG exerts its prophylactic effects in patients with SCLS. Over the last 8 to 10 years, monthly prophylaxis with IVIG has become the most commonly applied therapy in the NIH cohort. In the European registry 8 (44%) of 18 patients experienced no new attacks while receiving IVIG, some for prolonged periods of follow-up. 50 The dosing of IVIG ranged greatly in this study, from 0.4 to 2 g/kg/mo. Recently, we performed a questionnaire-based longitudinal study of IVIG therapy in 29 patients in our cohort. 55 Eighteen of 22 patients who responded had been treated with IVIG, with a median interval of 32 months (range, 10-59 months). Strikingly, median attack frequency decreased from 2.6 episodes per patient per year to zero after commencing IVIG prophylaxis (P 5 .0001). Fifteen of those 18 patients did not experience new SCLS episodes while receiving IVIG prophylaxis, and the side effect profile was favorable. Based on our analysis of the NIH cohort and recent published case reports in which a precise treatment history was provided, the median annual attack frequency in subjects treated with theophylline and terbutaline was 2.25 (range, 0-20; 27 patients). By contrast, median annual attack frequency in patients treated with IVIG or subcutaneous immunoglobulin was zero (range, 0-3.3; 40 patients).
In light of the impracticality of prospective randomized clinical trials, we now highly recommend empiric prophylaxis with IVIG as front-line therapy for newly diagnosed cases of SCLS and a history of severe episodes. Although the optimal dose and duration of IVIG therapy for SCLS remain to be established, most of our patients receive 2 g/kg/mo initially. In some cases doses have been tapered to 1 g/kg/mo after a prolonged initial remission period. We have not yet withdrawn IVIG therapy in any patient who has responded favorably. In the past, some patients were treated simultaneously with theophylline, terbutaline, and IVIG. However, we do not currently recommend this approach because in our experience treatment with theophylline and terbutaline frequently adds burdensome side effects without augmenting the efficacy of IVIG alone.
CONCLUSIONS
Treatment of acute SCLS remains primarily supportive. Prophylaxis with IVIG appears promising, but this therapy is nonspecific and expensive. Mechanistic understanding of SCLS is in its infancy. As a result, clinicians today cannot predict when or how badly SCLS will flare; targeted therapies do not yet exist, and prolonged remission or cure remains elusive. Our working hypothesis invokes exaggerated microvascular endothelial responses to surges of otherwise routinely encountered inflammatory mediators. This emerging disease model lends itself to innovative patient-centered translational research in the ways highlighted above. It is our hope that detailed and personalized investigation of intraendothelial responses among individual patients with SCLS might illuminate novel genetic and molecular control mechanisms. In turn, such advances could deliver the diagnostic, prognostic, and therapeutic tools sorely needed to combat this devastating disease.
